Known B cells undergo rearrangement of immunoglobulin (Ig) gene segments V-(D)-J and somatic hypermutation, generating a vast diversity of antibodies (theoretically at least 10^16 possible variants). This diversity allows recognition of nearly any foreign antigen surface, making it highly advantageous for the development of broadly neutralizing antibodies. It has also played a wide-ranging role and demonstrated value in scientific research, disease diagnosis and cancer treatment.

（Cyster JG, et al. Cell. 2019）

Strategies that involve the selection of single B cells, avoiding hybridoma fusion and combinatorial display technologies, have become crucial for effectively sampling immune animals and establishing natural neutralizing antibody libraries. Single B cell antibody development technology enables direct sampling of the immune repertoire, preserving natural heavy and light chain pairings and avoiding the inefficient hybridoma fusion step. This approach effectively explores the immune B cell population, facilitating the discovery of rare neutralizing antibodies with unique and highly desirable characteristics, as well as the generation of large and diverse neutralizing antibody libraries. Preserving the natural pairing of heavy and light chains during antibody gene cloning is advantageous for producing recombinant neutralizing antibodies with attractive affinity, specificity, and stability, a practice increasingly adopted by researchers.（Wei Chen, et al. Protein Expr Purif. 2021；Dale O Starkie, et al. PLoS One. 2016）。

（Cao Y, et al. Cell. 2020）

Built upon our proprietary single B cell antibody development platform, we can screen a large number of positive B cell clones from the peripheral blood and spleen B cells of immunized rabbits using only one-tenth of the B cell quantity. The diverse and abundant antibody molecules generated through this platform are fully capable of meeting your needs for the application of neutralizing antibodies.